Xbrane Biopharma AB (publ) (XBRANE.ST)
XBRANE.ST Stock Price Chart
Explore Xbrane Biopharma AB (publ) interactive price chart. Choose custom timeframes to analyze XBRANE.ST price movements and trends.
XBRANE.ST Company Profile
Discover essential business fundamentals and corporate details for Xbrane Biopharma AB (publ) (XBRANE.ST) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Feb 2016
Employees
65.00
Website
https://www.xbrane.comCEO
Martin Amark
Description
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
XBRANE.ST Financial Timeline
Browse a chronological timeline of Xbrane Biopharma AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 24 Oct 2025
Earnings released on 26 Aug 2025
EPS came in at kr 0.11 surpassing the estimated kr 0.01 by +878.84%, while revenue for the quarter reached kr 322.70M , beating expectations by +316.88%.
Earnings released on 8 May 2025
EPS came in at kr 0.01 surpassing the estimated -kr 0.03 by +133.33%, while revenue for the quarter reached kr 93.24M , missing expectations by -73.84%.
Earnings released on 21 Feb 2025
EPS came in at -kr 0.03 falling short of the estimated kr 0.01 by -400.00%, while revenue for the quarter reached kr 65.90M , missing expectations by -54.55%.
Earnings released on 24 Oct 2024
EPS came in at -kr 0.03 falling short of the estimated -kr 0.01 by -500.00%, while revenue for the quarter reached kr 66.81M , missing expectations by -67.79%.
Earnings released on 28 Aug 2024
EPS came in at -kr 0.05 falling short of the estimated -kr 0.04 by -25.00%, while revenue for the quarter reached kr 52.00M , missing expectations by -31.58%.
Earnings released on 16 May 2024
EPS came in at -kr 0.30 falling short of the estimated -kr 0.09 by -233.33%, while revenue for the quarter reached kr 14.07M , missing expectations by -78.97%.
Earnings released on 26 Feb 2024
EPS came in at -kr 0.35 surpassing the estimated -kr 0.38 by +6.71%, while revenue for the quarter reached kr 66.89M , beating expectations by +91.13%.
Stock split effective on 23 Feb 2024
Shares were split 441 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Nov 2023
EPS came in at -kr 2.78 surpassing the estimated -kr 3.06 by +9.15%, while revenue for the quarter reached kr 58.89M , beating expectations by +12.17%.
Earnings released on 29 Aug 2023
EPS came in at -kr 3.22 falling short of the estimated -kr 1.77 by -81.92%, while revenue for the quarter reached kr 51.10M , missing expectations by -43.22%.
Earnings released on 31 May 2023
EPS came in at -kr 2.12 falling short of the estimated -kr 1.25 by -69.60%, while revenue for the quarter reached kr 61.80M , beating expectations by +415.00%.
Earnings released on 17 Feb 2023
EPS came in at -kr 2.25 falling short of the estimated -kr 1.37 by -64.23%, while revenue for the quarter reached kr 20.86M , beating expectations by +127.03%.
Earnings released on 28 Oct 2022
EPS came in at -kr 1.67 falling short of the estimated -kr 1.29 by -29.46%, while revenue for the quarter reached kr 13.94M , missing expectations by -10.67%.
Earnings released on 22 Jul 2022
EPS came in at -kr 1.35 surpassing the estimated -kr 3.25 by +58.46%, while revenue for the quarter reached kr 15.63M , beating expectations by +212.62%.
Earnings released on 5 May 2022
EPS came in at -kr 1.50 surpassing the estimated -kr 2.64 by +43.18%, while revenue for the quarter reached kr 7.19M , beating expectations by +43.80%.
Earnings released on 24 Feb 2022
EPS came in at -kr 1.32 surpassing the estimated -kr 2.32 by +43.10%, while revenue for the quarter reached kr 11.53M , beating expectations by +140.30%.
Earnings released on 29 Oct 2021
EPS came in at -kr 1.83 surpassing the estimated -kr 2.32 by +21.12%, while revenue for the quarter reached kr 2.30M .
Earnings released on 13 Aug 2021
EPS came in at -kr 2.67 surpassing the estimated -kr 3.03 by +11.88%, while revenue for the quarter reached kr 2.49M .
Earnings released on 6 May 2021
EPS came in at -kr 2.31 surpassing the estimated -kr 3.04 by +24.01%, while revenue for the quarter reached kr 2.55M .
Earnings released on 26 Feb 2021
EPS came in at -kr 3.02 falling short of the estimated -kr 2.19 by -37.90%, while revenue for the quarter reached kr 6.82M .
Earnings released on 13 Nov 2020
EPS came in at -kr 2.99 falling short of the estimated -kr 2.87 by -4.18%.
XBRANE.ST Stock Performance
Access detailed XBRANE.ST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.